The Human SLC7A5 (LAT1): The Intriguing Histidine/Large Neutral Amino Acid Transporter and Its Relevance to Human Health

Человеческий SLC7A5 (LAT1): интригующий транспортер гистидина и крупных нейтральных аминокислот и его значение для здоровья человека
Lorena Pochini, Michele Galluccio, Cesare Indiveri, Mariafrancesca Scalise, Lara Console
2018-06-22

CD98 heterodimerCovalent LAT1 inhibitorsHistidine transportProteoliposome reconstitutionSLC7A5 (LAT1)
SLC7A5, known as LAT1, belongs to the APC superfamily and forms a heterodimeric amino acid transporter interacting with the glycoprotein CD98 (SLC3A2) through a conserved disulfide. The complex is responsible for uptake of essential amino acids in crucial body districts such as placenta and blood brain barrier. LAT1/CD98 heterodimer has been studied over the years to unravel the transport mechanism and the role of each subunit. Studies conducted in intact cells demonstrated that LAT1/CD98 mediates a Na+ and pH independent antiport of amino acids. Some novel insights into the function of LAT1 derived from studies conducted in proteoliposomes reconstituted with the recombinant human LAT1. Using this experimental tool, it has been demonstrated that the preferred substrate is histidine and that CD98 is not required for transport being, plausibly, involved in routing LAT1 to the plasma membrane. Since a 3D structure of LAT1 is not available, homology models have been built on the basis of the AdiC transporter from E.coli. Crucial residues for substrate recognition and gating have been identified using a combined approach of bioinformatics and site-directed mutagenesis coupled to functional assays. Over the years, the interest around LAT1 increased because this transporter is involved in important human diseases such as neurological disorders and cancer. Therefore, LAT1 became an important pharmacological target together with other nutrient membrane transporters. Moving from knowledge on structure/function relationships, two cysteine residues, lying on the substrate binding site, have been exploited for designing thiol reacting covalent inhibitors. Some lead compounds have been characterized whose efficacy has been tested in a cancer cell line.
1
Homology modeling, bioinformatics, mutagenesis, and functional assays identified residues involved in LAT1 substrate recognition and transport gating.
2
In intact cells, LAT1/CD98 mediates sodium- and pH-independent amino-acid antiport, while proteoliposome studies identify histidine as its preferred substrate.
3
LAT1 forms a heterodimer with CD98 through a conserved disulfide bond and transports essential amino acids in tissues including the placenta and blood–brain barrier.
4
LAT1 is implicated in neurological disorders and cancer; substrate-site cysteines have enabled development of covalent thiol-reactive inhibitors, with lead compounds tested in a cancer cell line.
5
Reconstituted human LAT1 can transport amino acids without CD98, suggesting CD98 primarily contributes to LAT1 trafficking to the plasma membrane.

Human SLC7A5/LAT1 amino acid transporter, including its LAT1/CD98 heterodimer and reconstituted recombinant human LAT1

LAT1 substrate specificity, transport mechanism, structural determinants of substrate recognition and gating, and its potential as a pharmacological target in human disease

Publication Details
Publication Date
2018-06-22
Journal
Publisher
ISSN
Cited by
297
Access Type
Author Information
Authors
Lorena Pochini
Michele Galluccio
Cesare Indiveri
Mariafrancesca Scalise
Lara Console
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%